CAS 129101-54-8|Rivastigmine (tartrate)

Introduction：Basic information about CAS 129101-54-8|Rivastigmine (tartrate), including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Rivastigmine (tartrate) BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Customs
6. Articles27
7. Synonyms

Common Name	Rivastigmine (tartrate)
CAS Number	129101-54-8	Molecular Weight	400.423
Density	/	Boiling Point	316.2ºC at 760 mmHg
Molecular Formula	C₁₈H₂₈N₂O₈	Melting Point	123-1250C
MSDS	Chinese	Flash Point	145ºC

Names

Name	rivastigmine tartrate
Synonym	More Synonyms

Rivastigmine (tartrate) BiologicalActivity

Description	Rivastigmine tartrate, an cholinesterase inhibitor(IC50= 5.5 uM), inhibits both butyrylcholinesterase and acetylcholinesteraseIC50 value: 5.5 uMTarget: AChERivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting. The drug is eliminated through the urine, and appears to have relatively few drug-drug interactions. Rivastigmine, a cholinesterase inhibitor, inhibits both butyrylcholinesterase and acetylcholinesterase. It is thought to work by inhibiting these cholinesterase enzymes, which would otherwise break down the brain chemical acetylcholine.
Related Catalog	Signaling Pathways >>Neuronal Signaling >>AChEResearch Areas >>Neurological Disease
References	[1]. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract. 2009 May;63(5):799-805. [2]. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998 Jul-Aug;20(4):634-47. [3]. Stryjer R, Ophir D, Bar F et al. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. Clin Neuropharmacol. 2012 Jul-Aug;35(4):161-4. [4]. Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol. 2011 Sep;7(3):137-42.

Description

Rivastigmine tartrate, an cholinesterase inhibitor(IC50= 5.5 uM), inhibits both butyrylcholinesterase and acetylcholinesteraseIC50 value: 5.5 uMTarget: AChERivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting. The drug is eliminated through the urine, and appears to have relatively few drug-drug interactions. Rivastigmine, a cholinesterase inhibitor, inhibits both butyrylcholinesterase and acetylcholinesterase. It is thought to work by inhibiting these cholinesterase enzymes, which would otherwise break down the brain chemical acetylcholine.

Related Catalog

Signaling Pathways >>Neuronal Signaling >>AChEResearch Areas >>Neurological Disease

References

[1]. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract. 2009 May;63(5):799-805.

[2]. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998 Jul-Aug;20(4):634-47.

[3]. Stryjer R, Ophir D, Bar F et al. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. Clin Neuropharmacol. 2012 Jul-Aug;35(4):161-4.

[4]. Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol. 2011 Sep;7(3):137-42.

Chemical & Physical Properties

Boiling Point	316.2ºC at 760 mmHg
Melting Point	123-1250C
Molecular Formula	C₁₈H₂₈N₂O₈
Molecular Weight	400.423
Flash Point	145ºC
Exact Mass	400.184570
PSA	147.84000
LogP	0.63710
Vapour Pressure	0.000416mmHg at 25°C
InChIKey	GWHQHAUAXRMMOT-MBANBULQSA-N
SMILES	CCN(C)C(=O)Oc1cccc(C(C)N(C)C)c1.O=C(O)C(O)C(O)C(=O)O
Storage condition	-20°C Freezer

Safety Information

Hazard Codes	Xi
Safety Phrases	36
RIDADR	NONH for all modes of transport
HS Code	2942000000

Customs

HS Code	2942000000

Articles27

[Effect of AChE and BuChE inhibition by rivastigmin in a group of old-old elderly patients with cerebrovascular impairment (SIVD type)].

Minerva Med. 105(2) , 167-74, (2014)

Vascular dementia (VaD) is defined as a loss of cognitive function resulting from ischemic, hypoperfusive, or hemorrhagic brain lesions due to cerebrovascular disease or cardiovascular pathology. The ...

Blood pro-inflammatory cytokines in Alzheimer's disease in relation to the use of acetylcholinesterase inhibitors.

Int. J. Geriatr. Psychiatry 28(12) , 1312-7, (2013)

A potential anti-inflammatory role for acetylcholinesterase inhibitors (AChEIs) has been supported by animal studies. As very limited data exist from individuals with Alzheimer's disease (AD), the aim...

Rivastigmine for vascular cognitive impairment.

Cochrane Database Syst. Rev. 5 , CD004744, (2013)

Vascular dementia represents the second most common type of dementia after Alzheimer's disease. In older patients, in particular, the combination of vascular dementia and Alzheimer's disease is common...

Synonyms

3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate 2,3-dihydroxybutanedioate (1:1)

acide (2R,3R)-2,3-dihydroxybutanedioïque - éthyl(méthyl)carbamate de 3-[(1S)-1-(diméthylamino)éthyl]phényle (1:1)

RivastigMine L-Tartrate

Rivastigmine Tartrate Salt

N-Ethyl-N-methylcarbamic Acid 3-[(S)-1-(Dimethylamino)ethyl]phenyl Ester L-Tartrate

Rivastigmine

(2R,3R)-2,3-Dihydroxysuccinic acid - 3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate (1:1)

(S)-3-(1-(Dimethylamino)ethyl)phenyl ethyl(methyl)carbamate (2R,3R)-2,3-dihydroxysuccinate

Rivastigmine Tartrate

3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate 2,3-dihydroxybutanedioate (salt)

(2R,3R)-2,3-Dihydroxybutandisäure--3-[(1S)-1-(dimethylamino)ethyl]phenyl-ethyl(methyl)carbamat(1:1)

3-[(S)-1-(Dimethylamino)ethyl]phenyl N-Ethyl-N-methylcarbamate L-Tartrate

Rivastigmine hydrogen tartrate

Rivastigmine (tartrate)

Recommended......